Mobile

The OPAL Study: A Phase II Single Arm Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006799-32

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to evaluate the efficacy of tosedostat in elderly subjects with treatment refractory or relapsed AML by measuring CR and CRp.

Critère d'inclusion

  • Treatment Refractory or Relapsed Acute Myeloid Leukemia

Liens